Updates in the Treatment of Pancreatic Cancer
Originally presented at HOPA's 13th Annual Conference, March 2017.
Over the past several years new chemotherapy regimens have demonstrated improvement in survival for patients with pancreatic cancer, however, with varying toxicity profiles. This session will review recent clinical data for the treatment of pancreatic cancer and provide guidance on selecting appropriate treatment plans for patients with metastatic disease.
- Summarize recent advancements in chemotherapy for the treatment of pancreatic cancer.
- Compare the benefits and limitations of chemotherapy regimens for the treatment of metastatic pancreatic cancer.
- Select a chemotherapy treatment plan for a patient with metastatic pancreatic cancer.
Andrea Landgraf Oholendt, PharmD BCOP
Andrea Landgraf Oholendt, is a manager for clinical pharmacy services in the Division of Pharmacy at the University of Texas MD Anderson Cancer Center in Houston. Her primary responsibilities include collaborating with the gastrointestinal medical oncology multidisciplinary team in the care of patients with gastrointestinal cancers. She received her PharmD degree from the University of Arizona in Tucson and completed a pharmacy practice residency at the Methodist Hospital in Houston, and an oncology pharmacy practice residency at MD Anderson Cancer Center. She became a board certified oncology pharmacist in 2006.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020